Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat

被引:48
|
作者
Masuda, Takahiro [1 ]
Watanabe, Yuko [1 ]
Fukuda, Keiko [1 ]
Watanabe, Minami [1 ]
Onishi, Akira [1 ]
Ohara, Ken [1 ]
Imai, Toshimi [1 ]
Koepsell, Hermann [2 ]
Muto, Shigeaki [1 ]
Vallon, Volker [3 ,4 ,5 ]
Nagata, Daisuke [1 ]
机构
[1] Jichi Med Univ, Dept Internal Med, Div Nephrol, Shimotsuke, Tochigi 3290498, Japan
[2] Univ Wurzburg, Dept Mol Plant Physiol & Biophys, Julius von Sachs Inst, Wurzburg, Germany
[3] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92103 USA
[4] Univ Calif San Diego, Dept Pharmacol, Div Nephrol & Hypertens, San Diego, CA 92103 USA
[5] VA San Diego Healthcare Syst, San Diego, CA USA
关键词
bioimpedance analysis; body fluid volume; diuresis; natriuresis; SGLT2; inhibition; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; SALT-SENSITIVE HYPERTENSION; RENAL GLUCOSE REABSORPTION; GLOMERULAR HYPERFILTRATION; BLOOD-PRESSURE; PROXIMAL TUBULE; PLASMA-VOLUME; AKITA MICE; OBESE RATS;
D O I
10.1152/ajprenal.00143.2018
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The chronic intrinsic diuretic and natriuretic tone of sodium-glucose cotransporter 2 (SGLT2) inhibitors is incompletely understood because their effect on body fluid volume (BFV) has not been fully evaluated and because they often increase food and fluid intake at the same time. Here we first compared the effect of the SGLT2 inhibitor ipragliflozin (Ipra, 0.01% in diet for 8 wk) and vehicle (Veh) in Spontaneously Diabetic Torii rat, a nonobese type 2 diabetic model, and nondiabetic Sprague-Dawley rats. In nondiabetic rats, Ipra increased urinary excretion of Na+ (UNaV) and fluid (UV) associated with increased food and fluid intake. Diabetes increased these four parameters, but Ipra had no further effect, probably because of its antihyperglycemic effect, such that glucosuria and, as a consequence, food and fluid intake were unchanged. Fluid balance and BFV, determined by bioimpedance spectroscopy, were similar among the four groups. To study the impact of food and fluid intake, nondiabetic rats were treated for 7 days with Veh, Ipra, or Ipra+pair feeding+pair drinking (Pair-Ipra). Pair-Ipra maintained a small increase in UV and UNaV versus Veh despite similar food and fluid intake. Pair-Ipra induced a negative fluid balance and decreased BFV, whereas Ipra or Veh had no significant effect compared with basal values. In conclusion, SGLT2 inhibition induces a sustained diuretic and natriuretic tone. Homeostatic mechanisms are activated to stabilize BFV, including compensatory increases in fluid and food intake.
引用
收藏
页码:F653 / F664
页数:12
相关论文
共 50 条
  • [21] Beyond Glycosuria: Exploring the intrarenal effects of SGLT2 inhibition in diabetes
    Thomas, M. C.
    Jandeleit-Dahm, K.
    Bonnet, F.
    DIABETES & METABOLISM, 2014, 40 : S17 - S22
  • [22] The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
    Ken Ohara
    Takahiro Masuda
    Masato Morinari
    Mari Okada
    Atsushi Miki
    Saki Nakagawa
    Takuya Murakami
    Kentaro Oka
    Maki Asakura
    Yasuharu Miyazawa
    Akito Maeshima
    Tetsu Akimoto
    Osamu Saito
    Daisuke Nagata
    Diabetology & Metabolic Syndrome, 12
  • [23] Metabolic Communication by SGLT2 Inhibition
    Billing, Anja M.
    Kim, Young Chul
    Gullaksen, Soren
    Schrage, Benedikt
    Raabe, Janice
    Hutzfeldt, Arvid
    Demir, Fatih
    Kovalenko, Elina
    Lasse, Moritz
    Dugourd, Aurelien
    Fallegger, Robin
    Klampe, Birgit
    Jaegers, Johannes
    Li, Qing
    Kravtsova, Olha
    Crespo-Masip, Maria
    Palermo, Amelia
    Fenton, Robert A.
    Hoxha, Elion
    Blankenberg, Stefan
    Kirchhof, Paulus
    Huber, Tobias B.
    Laugesen, Esben
    Zeller, Tanja
    Chrysopoulou, Maria
    Saez-Rodriguez, Julio
    Magnussen, Christina
    Eschenhagen, Thomas
    Staruschenko, Alexander
    Siuzdak, Gary
    Poulsen, Per L.
    Schwab, Clarissa
    Cuello, Friederike
    Vallon, Volker
    Rinschen, Markus M.
    CIRCULATION, 2024, 149 (11) : 860 - 884
  • [24] SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
    Chen, Huan
    Birnbaum, Yochai
    Ye, Regina
    Yang, Hsiu-Chiung
    Bajaj, Mandeep
    Ye, Yumei
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) : 1091 - 1108
  • [25] Nephroprotection via SGLT2 inhibition
    Wanner, C.
    DIABETOLOGE, 2018, 14 (02): : 93 - 95
  • [26] More CREDENCE for SGLT2 Inhibition
    Verma, Subodh
    Bhatt, Deepak L.
    CIRCULATION, 2019, 140 (18) : 1448 - 1450
  • [27] Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
    DeFronzo, Ralph A.
    Norton, Luke
    Abdul-Ghani, Muhammad
    NATURE REVIEWS NEPHROLOGY, 2017, 13 (01) : 11 - 26
  • [28] The potential anti-arrhythmic effect of SGLT2 inhibitors
    Duan, Hong-Yi
    Barajas-Martinez, Hector
    Antzelevitch, Charles
    Hu, Dan
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [29] SGLT1 does compensate for SGLT2 inhibition
    Javier Martinez-Martin, Francisco
    Jimenez-Martin, Natalia
    Sablon-Gonzalez, Nery
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (04) : 256 - 256
  • [30] SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier
    Aguiar-Neves, Ines
    Santos-Ferreira, Diogo
    Fontes-Carvalho, Ricardo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (01)